News Related to Nerandomilast

Related coverage linked through entity extraction aliases.

Pharmaceutical Market Forecasts: Respiratory, Fibrosis, and Digital Health Segments Project Growth

Jun 06, 2026

Recent market reports forecast significant growth in the progressive pulmonary fibrosis market, set to reach $2.7 billion by 2035, and the global asthma and COPD drugs market, projected to hit US$ 82.2 billion by 2036. The Asia Pacific pharma 4.0 market is also expanding rapidly, driven by digital technologies like AI and IoT.

Deupirfenidone Advances to Phase 3 Trial for Idiopathic Pulmonary Fibrosis

Mar 21, 2026

Deupirfenidone, a deuterated form of pirfenidone, is set to be tested in a phase 3 trial this year after successful phase 2b results. The FDA and European Commission have granted orphan drug designation to support its late-stage development.